Previous studies have shown that RUNX2 contributes to the progression of breast and prostate cancer-related osteolytic bone destructions by inducing TGFβ signaling and the CTGF-RUNX2-RANKL axis [17–19]. Here, RUNX2 is linked to prostate carcinoma.